专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050266510A1 T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase 有权
标题翻译： T细胞无反应通过活性Ras逆转并受二酰基甘油激酶调控
公开(公告)号：US20050266510A1
公开(公告)日：2005-12-01
申请号：US11032516
申请日：2005-01-10
申请人： Thomas Gajewski
发明人： Thomas Gajewski
IPC分类号： C12Q1/48 , G01N33/50
CPC分类号： G01N33/505 , C12Q1/485
摘要： T cell anergy has been correlated with defective Ras signaling. However, neither a causal relationship nor the mechanism of Ras hypoactivation have been established. Using adenoviral transduction of CAR Tg T cells to enable genetic manipulation in nonproliferating cells, we show that Ras61L restores IL-2 production and MAP kinase signaling in T cells anergized in vitro or in vivo. A gene array screen revealed upregulated diacylglycerol kinase (DGK) in the anergic state, which was confirmed by RT-PCR and Western blot analysis. A DGK inhibitor significantly restored IL-2 production by anergic cells. Our data support a causal role for DGK and defective Ras signaling in T cell anergy.
摘要翻译： T细胞无反应与缺陷型Ras信号传导相关。然而，既没有建立起因果关系，也没有建立Ras hypoactivation的机制。使用CAR Tg T细胞的腺病毒转导使得在非增殖细胞中能够进行遗传操作，我们显示Ras61L在体外或体内释放的T细胞中恢复IL-2产生和MAP激酶信号传导。基因阵列屏幕显示在无能状态下上调二酰基甘油激酶（DGK），其通过RT-PCR和Western印迹分析证实。 DGK抑制剂显着恢复了无细胞的IL-2产生。我们的数据支持DGK和T细胞无反应性缺陷Ras信号传导的因果作用。

2. 发明申请

US20050037369A1 Panels of molecular targets differentially expressed during CD8+ T cell priming, and methods for therapy and diagnosis utilizing the same 审中-公开
标题翻译：在CD8 + T细胞引发期间差异表达的分子靶标面板，以及使用其的治疗和诊断方法
公开(公告)号：US20050037369A1
公开(公告)日：2005-02-17
申请号：US10698350
申请日：2003-10-31
申请人： Kuldeep Neote , Panayiotis Zagouras , Thomas Gajewski
发明人： Kuldeep Neote , Panayiotis Zagouras , Thomas Gajewski
IPC分类号： A61K20060101 , C12Q1/68 , C40B30/04 , G01N33/53 , G01N33/543
CPC分类号： C40B30/04 , C12Q1/6876 , C12Q2600/136 , C12Q2600/158
摘要： The present invention provides novel panels of molecular targets that are differentially expressed during CD8+ T cell priming. The novel panels of the invention may be used, for example, in therapeutic intervention, therapeutic agent screening, and in diagnostic methods for diseases and/or disorders of the immune system.
摘要翻译：本发明提供了在CD8 + T细胞引发期间差异表达的分子靶标的新颖小组。本发明的新颖小组可用于例如治疗干预，治疗剂筛选和用于免疫系统疾病和/或病症的诊断方法。

3. 发明授权

US5851523A Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof 失效
标题翻译：分离，衍生自与HLA-A2分子复合的MAGE肿瘤排斥抗原前体的肽及其用途
公开(公告)号：US5851523A
公开(公告)日：1998-12-22
申请号：US290381
申请日：1994-08-15
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
IPC分类号： G01N33/574 , A61K35/14 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/04 , C07K7/06 , C07K14/47 , C07K14/54 , C07K14/82 , C07K16/30 , C12N5/06 , C12N15/02 , C12P21/08 , A61K39/385
CPC分类号： C07K14/4748 , A61K38/00
摘要： Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
摘要翻译：已经鉴定了源自MAGE肿瘤排斥前体的肿瘤排斥抗原。这些“TRAS”与MHC-I类分子HLA-A2结合，并且所得复合物刺激裂解呈递细胞的溶细胞T细胞克隆的产生。肽和复合物可以用于诊断，治疗和用作产生抗体的免疫原，或用作产生溶细胞T细胞克隆的靶标。

4. 发明授权

US5591430A Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof 失效
标题翻译：与HLA-A2分子复合的分离的MAGE-3衍生的肽及其用途
公开(公告)号：US5591430A
公开(公告)日：1997-01-07
申请号：US261160
申请日：1994-06-17
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
IPC分类号： A61K38/00 , C07K14/47 , A61K38/08 , C07K14/82 , C12N5/06
CPC分类号： C07K14/4748 , A61K38/00 , Y10S530/828 , Y10S530/865
摘要： Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
摘要翻译：已经鉴定了源于肿瘤排斥前体MAGE-3的肿瘤排斥抗原。这些“TRAS”与MHC-I类分子HLA-A2结合，并且所得复合物刺激裂解呈递细胞的溶细胞T细胞克隆的产生。肽和复合物可以用于诊断，治疗和用作产生抗体的免疫原，或用作产生溶细胞T细胞克隆的靶标。

5. 发明申请

US20070212276A1 Catalytic reactor 有权
标题翻译：催化反应器
公开(公告)号：US20070212276A1
公开(公告)日：2007-09-13
申请号：US11373239
申请日：2006-03-13
申请人： Vasilis Papavassiliou , Shawn Cecula , Perry Pacouloute , Thomas Gajewski
发明人： Vasilis Papavassiliou , Shawn Cecula , Perry Pacouloute , Thomas Gajewski
IPC分类号： B01J8/02 , H01M8/06 , B01J19/26
CPC分类号： B01J19/2485 , B01J8/025 , B01J8/0278 , B01J8/0285 , B01J19/26 , B01J2208/00495 , B01J2208/00504 , B01J2208/00522 , B01J2208/00849 , B01J2208/00884 , B01J2219/00155 , B01J2219/00157 , B01J2219/00265 , C01B3/386 , C01B2203/0261 , C01B2203/1023 , C01B2203/1282
摘要： A catalytic reactor having a mixing section connected to a downstream reaction section containing a catalyst to promote a reaction of oxygen and a hydrocarbon fed to the catalytic reactor. The mixing section is provided with a flame arrestor to prevent a stable flame from propagating should any reaction of oxygen and hydrocarbons occur during mixing. The flame arrestor permits flow in both axial and radial directions to promote mixing. Baffle elements and a downstream static mixer can also be used. The catalyst is preferably in the form of monolithic blocks enclosed by a ceramic tube that is maintained as a unitary catalyst assembly that can be removed for replacement and installation of the catalyst as a single unit.
摘要翻译：一种催化反应器，其具有连接到下游反应部分的混合部分，所述下游反应部分含有催化剂以促进氧气和供给到催化反应器的烃的反应。如果在混合过程中发生氧和烃的任何反应，混合部分设有阻火器，以防止稳定的火焰传播。阻火器允许在轴向和径向方向上流动以促进混合。也可以使用挡板元件和下游静态混合器。催化剂优选为由陶瓷管封闭的整体块的形式，其被保持为可以作为单个单元替换和安装催化剂的单一催化剂组件。

6. 发明授权

US06682731B1 Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules 有权
标题翻译：衍生自与HLA-A2分子复合的法师肿瘤排斥抗原前体的分离的肽
公开(公告)号：US06682731B1
公开(公告)日：2004-01-27
申请号：US09533499
申请日：2000-03-23
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
IPC分类号： A61K4500
CPC分类号： C07K14/705 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K14/4748
摘要： Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
摘要翻译：可以使用SEQ ID NO：12和HLA-A2的复合物来产生CTL。可补充IL-6和IL-12。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式